Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F4ZY
|
|||
| Former ID |
DCL000312
|
|||
| Drug Name |
Istradefylline
|
|||
| Synonyms |
KW 6002; Istradefylline [USAN:INN]; Istradefylline (JAN/USAN/INN); (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 8-((1E)-2-(3,4-Dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Approved | [1] | |
| Substance use disorder [ICD-11: 6C4Z] | Phase 1 | [2] | ||
| Company |
Kyowa Hakko Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H24N4O4
|
|||
| Canonical SMILES |
CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C
|
|||
| InChI |
1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
|
|||
| InChIKey |
IQVRBWUUXZMOPW-PKNBQFBNSA-N
|
|||
| CAS Number |
CAS 155270-99-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7978842, 11056223, 12014869, 14878146, 39340766, 47206484, 50027674, 50629398, 57359333, 85210094, 92729739, 103276933, 104061724, 114155109, 126671671, 134338968, 134339069, 134343014, 135175557, 135697573, 137005694, 140175846, 144116113, 152105687, 152159601, 152258274, 152343827, 160647112, 162011669, 162222240, 163408039, 163914047, 164777218, 170466116, 172093763, 172912718, 174527720, 175437836, 178102242, 179150002, 185975314, 198959942, 206245955, 208265417, 223378751, 223435458, 223496120, 223554827, 223660299, 223704923
|
|||
| ChEBI ID |
CHEBI:134726
|
|||
| ADReCS Drug ID | BADD_D02484 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Modulator | [1] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Parkinson's disease | ||||
| Alcoholism | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Reactome | NGF-independant TRKA activation | |||
| Adenosine P1 receptors | ||||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Nucleotide GPCRs | |||
| Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.